老年人红细胞膜唾液酸含量与红细胞免疫功能的相关性

目的探讨老年人红细胞膜唾液酸（ＲＢＣｍ－ＳＡ）与红细胞免疫功能的相关性。方法采用Ｂｉａｌｓｃｈｅ试剂法检测ＲＢＣｍ－ＳＡ，Ｆ－８８３６化学比色法检测血浆唾液酸（Ｐ－ＳＡ），红细胞免疫粘附试验观察红细胞Ｃ３ｂ受体花环率（ＲＲＣＦ）。结果老年急性心肌梗死（ＡＭＩ）组和脑梗塞（ＡＣＩ）组的ＲＢＣｍ－ＳＡ分别为３０．８±４．３和３１．３±４．４μｇＮＡＮＡ／ｍｇ膜蛋白，ＲＲＣＦ分别为１６．７％±３．５％和１６．０％±３．６％，均低于老年对照组（Ｐ＜０．０１或０．０５），老年对照组均低于非老年对照组（均为Ｐ＜０．０５）；ＡＭＩ和ＡＣＩ患者的Ｐ－ＳＡ分别为２．４±０．４和２．４±０．３ｍｍｏｌ／Ｌ，均高于老年对照组（均为Ｐ＜０．０５），老年对照组则高于非老年对照组（Ｐ＜０．０５）。老年患者和老年对照组的ＲＢＣｍ－ＳＡ与ＲＲＣＦ均呈正相关，而ＲＢＣｍ－ＳＡ与Ｐ－ＳＡ均呈负相关。结论老年人红细胞Ｃ３ｂ受体花环率降低与ＲＢＣｍ－ＳＡ代谢障碍有关。     

冠状动脉重建术后氧输送和氧耗关系的探讨

观察３０例冠状动脉旁路移植术（ＣＡＢＧ）后氧输送指数（ＤＯ２Ｉ）、氧耗指数（ＶＯ２Ｉ）及其关系。其中单纯ＣＡＢＧ１５例，伴左室室壁瘤切除１２例，心脏瓣膜替换３例。全组架１～４支桥者分别是１０、８、８、４例。结果２９例成活，１例死亡。成活组术后即刻至３小时ＤＯ２Ｉ提高１０．６％（Ｐ＜０．０５）。ＶＯ２Ｉ增高１５．８％（Ｐ＜０．０１）．术后１４小时较６小时ＤＯ２Ｉ增加１５．８％（Ｐ＜０．０１），而ＶＯ２Ｉ降低４．４％。死亡例即刻至３小时ＤＯ２Ｉ增加６．０％，ＶＯ２Ｉ却降低２９．１％，死于多器官功能衰竭。资料表明，作为ＣＡＢＧ术后正常恢复经过，早期ＤＯ２Ｉ升高的同时ＶＯ２Ｉ也升高，此时，细胞内氧化磷酸化得到改善，氧债得到清偿。氧输送和氧耗达到平衡后ＶＯ２Ｉ不再增加。可见ＣＡＢＧ术后维持满意ＤＯ２Ｉ非常重要。     

冠心病合并左心功能不全患者冠状动脉旁路移植术效果

总结１５１例左室射血分数（ＬＶＥＦ）＜４５％患者的冠状动脉旁路移植术（ＣＡＢＧ）效果。方法单纯ＣＡＢＧ组６１例，平均ＬＶＥＦ（４０．８±３．７）％，平均塔桥３．６支；ＣＡＢＧ合并其它手术组９０例，平均ＬＶＥＦ（３４．４±７．１）％，平均搭桥１．８支，合并手术包括室壁瘤切除或成形８７例，瓣膜置换３例。结果两组分别死亡２例和６例，心律失常和术后低心排是手术死亡的主要原因。平均随访３４个月，随访率为９２％，两组各死亡２例，其中３例与心脏因素有关。两组ＬＶＥＦ分别为（５５．６±７．３）％和（５０．４±１１．４）％，较术前有明显提高（Ｐ＜０．０１）。术前心绞痛症状基本消失。早晚期病死率没有明显差异（Ｐ＞０．０５）。结论ＣＡＢＧ对伴有左心功能不全的冠心病患者是一种安全有效的治疗方法。移植血管应尽可能应用乳内动脉，以提高远期效果。加强围术期的处理，调整心脏的前后负荷，兼顾心肌氧需和氧耗平衡，必要时应用主动脉内球囊反搏或左室辅助（ＬＶＡＤ），以提高手术效果。     

老年人24小时动态血压正常值研究

探讨老年人２４ｈ动态血压（２４ｈＡＢＰ）波动规律，波动范围及正常值。方法采用ＢＰ－５０型无袖带式ＡＢＰ监测仪观察健康体检和非高血压住院的老年人２４ｈＡＢＰ变化。结果老年人２４ｈＡＢＰ波动规律呈峰谷变化和昼高夜低的特点。以均值±２个标准差为正常值，其均值范围为（１）２４ｈ平均血压１０９～１３５／６８～８３ｍｍＨｇ；（２）夜间下降率７．０％～１１．８％（ＳＢＰ）／１．２％～４．４％（ＤＢＰ）；（３）血压负荷６．８％～１２．８％／３．７％～６．５％。结论上述三项指标可作为老年人２４ｈＡＢＰ判定标准，大于正常可诊断高血压。     

呋喃唑酮与胶体铋剂联合应用治疗幽门螺杆菌相关性胃炎的疗效观察

应用胶体铋剂（ＣＢＳ）与不同剂量的呋喃唑酮（Ｆ）联合治疗Ｈｐ阳性慢性胃炎患者。１７３例病人随机分为５组（ＣＢ８组、Ｆ０．２组、ＣＢＳ＋Ｆ０．２组、ＣＢＳ＋Ｆ０．１组、ＣＢＳ＋Ｆ０．０５组）服药４周（ＣＢＳ４周＋Ｆ２周），Ｈｐ根除率分别为２３．３％、５９．３％、１００％、９１．３％和６１．９％；活动性胃炎消退率分别为１４．０％、４８．１％、７０．９％、８６．７％和５３．３％；副作用发生率分别为４．６％、２１．８％、２３．５％、７．１％和１４．８％。ＣＢＳ＋Ｆ０．２及ＣＢＳ＋Ｆ０．１组Ｈｐ根除率及活动性胃炎消退率均显著高于其它三组（Ｐ＜００５）；且ＣＢＳ＋Ｆ０．１与ＣＢＳ＋Ｆ０．２疗效相当，Ｈｐ根除率可达９０％以上，副作用程度明显减轻，是较理想的根除Ｈｐ方案。     

替普瑞酮对胃溃疡愈合及其愈合质量的影响

为了研究替普瑞酮对胃溃疡的治疗效果，对１０６例经胃镜证实的胃溃疡病人，随机分为Ａ组（替普瑞酮＋西咪替丁）和Ｂ组（单用西咪替丁）。４周溃疡愈合率Ａ、Ｂ两组分别为７２．４％和５２．１％（Ｐ＜０．０５），８周为９３．１％和８９．６％（Ｐ＞０．０５）；Ｓ２期的获得率４周分别为３４．５％和１０．４％，８周为５０．０％和２０．８％（Ｐ＜０．００５）。氨基己糖测定：Ａ组治疗后（１７．７９±２．００μｇ／ｍｇ）明显高于治疗前（１４．２７±２．４７μｇ／ｍｇ）（Ｐ＜０．０５），而Ｂ组治疗前后则无明显变化。本研究结果强烈提示Ａ组加用替普瑞酮不仅加速了胃溃疡的愈合，而且显示溃疡愈合质量亦明显高于单用西咪替丁组，这可能与替普瑞酮显著增加氨基己糖含量有关     

原发性肝癌组织P16蛋白的缺失与HBV感染

目的研究Ｐ１６蛋白缺失与原发性肝癌发生发展的关系以及ＨＢＶ感染与Ｐ１６蛋白缺失的相关性．方法用免疫组化技术（ＬＳＡＢ法）检测７０例原发性肝癌组织标本中的Ｐ１６蛋白和ＨＢｓＡｇ．结果有６０６％（４０／６６）的肝细胞癌（ＨＣＣ）和７５０％（１／４）的胆管细胞癌（ＣＣＣ）Ｐ１６蛋白缺失；Ⅰ，Ⅱ，Ⅲ和Ⅳ级（按Ｅｄｍｏｎｄｓｏｎ标准）ＨＣＣＰ１６蛋白缺失率分别为００％（０／１），４４１％（１５／３４），８２１％（２３／２８）和６６７％（３／４），组间差异显著（Ｐ＜００５）．在有癌旁肝组织的４８例标本中，癌组织Ｐ１６蛋白阴性率（７２６％）明显高于癌旁肝组织（４１２％，Ｐ＜００５）．有６２５％（３０／４８）的ＨＣＣ癌旁肝组织ＨＢｓＡｇ阳性．ＨＢｓＡｇ阳性病例与阴性病例的Ｐ１６阴性率分别为７３３％（２２／３０）和６６７％（１２／１８），差异无显著性（Ｐ＞００５）．结论Ｐ１６蛋白缺失与原发性肝癌相关，与肝癌的恶性发展关系密切，可能对预后有重要影响．ＨＢＶ感染与Ｐ１６蛋白缺失无明显相关性．     

经食管电生理检查中的交替文氏现象

在５６１例经食管电生理检查中，检出各类交替文氏现象（ＡＷ）８１例，共１３７例次，占１４．４％，其中Ａ型、Ｂ型、ＡＢ混合型、三层房室ＡＷ分别为４４，６０，１８，６例次，分别占３２．１％、４３．８％、１３．１％、４．４％；房室结双径路间、束支、房室旁束的ＡＷ分别为５，２，２例次，分别占３．６％、１．５％、１．５％。将７９例ＡＷ者（Ａ组）与８０例无ＡＷ者（Ｂ组）的电生理资料进行比较，显示：①窦性心率（ＳＲ），Ａ组较Ｂ组慢（７２±１４．２ｂｐｍｖｓ７８±１２．６ｂｐｍ，Ｐ＜０．００１）。②房室相对不应期（ＡＶＲＲＰ）、房室功能不应期（ＡＶＦＲＰ）、房室有效不应期（ＡＶＥＲＰ），Ａ组分别为６０９．０±１１９．４，４９６．６±９６．０，３６０．０±８８．０ｍｓ，与Ｂ组（５４６．０±６８．９，４２９．３±６１．５，３０７．０±５１．３ｍｓ）比较差异有高度显著性，Ｐ均＜０．００１。③心房有效不应期（ＡＥＲＰ），Ａ组与Ｂ组比较无显著差异（２６５．０±４２．３ｍｓｖｓ２６５．０±３７．３ｍｓ，Ｐ＞０．０５）。④随Ｓ１Ｓ１刺激间距缩短，Ａ组的房室传导顺序为：１１→文氏型→２１→交替文氏型→３１或心房Ｐ波脱漏；Ｂ组的房室传导顺序则?     

拉米夫定、治肝灵冲剂联合治疗慢性乙型肝炎近期疗效研究

研究单用拉米夫定（３－ＴＣ）及联合应用中药治肝灵冲剂对慢性乙型肝炎（ＣＨＢ）的治疗作用，探讨两者联合治疗的近期疗效和安全性。５０例ＣＨＢ患者随机分为Ａ，Ｂ两组，Ａ组采用３－ＴＣ和治肝灵冲剂联合治疗；Ｂ组单用３—ＴＣ，疗程均为６个月，治疗前、治疗２周、４周、８周、１２周、１６周，２０周、２６周分别检测ＨＢＶ标志、肝功能，血清学指标，肾功能，并记录治疗期间临床和实验室检查发生的一切不良事件。治疗２６周后Ａ组血清ＨＢｅＡｇ转阴率６４．０％（１６／２５）．明显高于Ｂ组１６．０％（４／２５）Ｐ＜０．０１． Ａ组与Ｂ组分别有４例（１６．０％），２例（８．０％）实现ＨＢｅＡｇ血清转换。Ｐ＞０．０５。转阴患者未发现ＨＢＶ前Ｃ区变异株。Ａ组和Ｂ组ＨＢＶＤＮＡ转阴例数分别为２４（９６．０％）和２３（９２．０％）Ｐ＞０．０５。治疗结束时Ａ组和Ｂ组ＡＬＴ的复常率分别为８８．０％（２２／２５）、６４．０％（１６／２５），Ｐ＜０．０５。采用３－ＴＣ与治肝灵冲剂联合治疗ＣＨＢ，短期疗效明显优于单一用药组，且副作用少，是安全、有效的治疗ＣＨＢ的方案。     

自体外周血干细胞的动员和采集及其移植效果的研究

对２２例自体外周血干细胞移植（ＡＰＢＳＣＴ）的三种动员方案、采集方法及移植的外周血干细胞（ＰＢＳＣ）数量与造血重建关系，进行了研究。２２例中急性白血病１１例，多发性骨髓瘤６例，非何杰金淋巴瘤４例，晚期乳癌１例。三组动员方案：化疗十四氢叶酸＋氟美松；化疗＋ｒｈＧＭ－ＣＳＦ（重组人粒巨噬细胞集落刺激因子）＋氟美松；化疗＋ｒｈＧ－ＣＳＦ（重组人粒细胞集落刺激因子）＋氟美松。用流式细胞计双染直接免疫荧光法测定ｒｈＧ－ＣＳＦ方案组中７例ＣＤ３４＋／ＣＤ３３￣＋细胞。结果表明：（１）ｒｈＧ－ＣＳＦ方案组的ＰＢＳＣ产率最高，平均每例ＭＮＣ（单个核细胞）（８．２９±６．１４）×１０￣８／ｋｇ，ＣＦＵ－ＧＭ（粒单系祖细胞集落生成单位）（２１．３５±１７．２４）×１０￣４／ｋｇ。（２）ＣＤ３４＋细胞数与ＭＮＣ及ＣＦＵ－ＧＭ数大致相关。ＣＤ３４￣＋细胞在动员前外周血中多为０或＜０．５％，动员后约在用ｒｈＧ－ＣＳＦ后６～８天明显增多，就可连续每日采集，如达到≥５×１０￣５／ｋｇ即可停止。（３）采集与回输的ＰＢＳＣ数量是决定造血重建的关键。     

Impact of health education on the prevalence of enterobiasis in Korean preschool students

Health education has been shown to be effective in slowing the spread of the disease, infectious disease in particular. To evaluate the impact of health education on the prevalence and pattern of new infection of enterobiasis, children from 6 kindergartens in Ulsan city, South Korea, were recruited after undergoing a screening for enterobiasis, and then divided into three groups, including group medication (GM), education (Edu), and control group. All children in GM group received medical treatment with 500 mg albendazole twice, with 15 days interval. In the Edu group, only children diagnosed positive for Enterobius vermicularis eggs received medical treatment with 500 mg albendazole twice, with 15 days interval and all parents in the group received brochures providing information about enterobiasis. In the control group, only children diagnosed positive for E. vermicularis eggs received medical treatment with 500 mg albendazole twice, with 15 days interval, and no information about enterobiasis was provided to parents. Two post-treatment examinations were performed at three and six months after treatment. The infection rate in the GM group was dramatically decreased at 3 months, and this rate was almost the same as at 6 months after treatment. Infection rate of children in the Edu group was shown to drop from 9.9% to 3.0% at 3 months, and to 2.7% at 6 months after treatment; however, the infection rate in the control group continued to be higher than in the other two groups at both 3 and 6 months, with smaller change at 3 months compared to the other two groups. In addition, both new infection and re-infection cases in the Edu group were fewer, compared to those in the control group. In conclusion, although GM is the best method for eradication of enterobiasis, providing health information about enterobiasis to parents could reduce the prevalence, as well as the rate of new infection or re-infection with E. vermicularis in their children.     

聚乙二醇干扰素α-2a、阿德福韦酯单用及联合应用治疗HBeAg阳性慢性乙型肝炎患者的疗效及安全性比较

目的 比较聚乙二醇干扰素α-2a、阿德福韦酯单药治疗及两药联合治疗慢性乙型肝炎的疗效及安全性.方法 采用开放、随机、对照、多中心临床试验,将120例HBeAg阳性入选病例分为聚乙二醇干扰素α-2a组(A组)40例、阿德福韦酯组(B组)40例和聚乙二醇干扰素α-2a加阿德福韦酯组(C组)40例.分别在治疗24周和48周及随访48周时进行疗效、安全性及耐药评估.应答疗效比较采用X2检验.结果 113例纳入分析,其中A组2例、C组5例未按设计要求进行治疗被剔除.治疗48周时,病毒学应答(HBV DNA≤500拷贝/mL)在A组为14例,B组为15例,C组为22例,以C组疗效为佳(C组与A、B组比较,X2=4.933、4.801,均P<0.05);HBeAg血清学转换在A组为17例、B组为7例、C组为18例.随访48周时,获得持久应答病例在A组为13例,B组为6例,C组为17例,C组及A组显著高于B组(X2=9.894,P<0.01;X2=3.903,P<0.05),而C组与A组相近(X2=1.552,P>0.05).结论 聚乙二醇干扰素α-2a与阿德福韦酯联合治疗在疗程24周及48周时的病毒学应答均优于两药单独治疗时的效果,随访48周时联合治疗组与单用聚乙二醇干扰素α-2a组的持久应答疗效优于单用阿德福韦酯组.     

Multidrug regimens for treatment of older patients with metastatic pancreatic cancer

Background and AimsOlder patients with metastatic pancreatic adenocarcinoma (MPDAC) are under-represented in clinical trials.MethodsOur single-center, retrospective study enrolled MPDAC patients ≥ 70 treated with chemotherapyResults105 patients were divided in groups based on the received treatments: 44 gemcitabine or capecitabine monotherapy (A), 34 nabpaclitaxel-gemcitabine (B) 27 4-drugs combinations (gemcitabine, cisplatin, capecitabine plus either nab-paclitaxel or epirubicin or docetaxel) (C). Group A: median age was 78 (70–87) and Karnofsky performance status (KPS) ≥80 was found in 84% of patients; Group B: median age 77 (71–84) and KPS ≥ 80 in 88% of patients; Group C: median age 73 (70–78) and KPS ≥ 80 in 93% of patients. Median OS was 7.9, 11.7 and 14.2 months in group A, B and C respectively; 1 and 2-year OS were 27% and 8% in group A; 44% and 5% in group B; 52% and 22% in group C. When lung metastatic only patients were excluded, patients <75 and ≥ 75 had similar OS in group A (6.4 vs 5.6 months) and in group B (12.3 vs 11.1 months). In group B grade 3 thrombocytopenia, fatigue and peripheral neuropathy were more frequent in patients ≥ 75.ConclusionsIn older patients, combination chemotherapy shows acceptable feasibility and promising efficacy.     

The dismal outcome in patients with acute leukaemia who relapse after an autograft is improved if a second autograft or a matched allograft is performed. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)

All patients receiving autografts for acute leukaemia in remission between 1 January 1981 and 31 December 1996 and reported to the European Group for Blood and Marrow Transplantation and had a relapse, were included. The patients underwent an allograft (n = 90, group A), were treated with chemotherapy (n = 2584, group B) or received a second autograft (n = 74, group C). The 2-year survival after relapse was 32 +/- 5%, 11 +/- 1% and 42 +/- 6% in groups A, B and C, respectively. In group A, those with an HLA-A, -B and -DR compatible related or unrelated donor had a 2-year survival of 37 +/- 7% compared to 13 +/- 8% for those receiving a graft from an HLA mismatched donor (n = 20). The following factors were associated with better survival in multivariate analyses: an interval from first autograft to relapse >5 months (P < 0.00001), a first autograft performed later than 1991 (P < 0.00001), patient age below 26 years (median, P < 0.002), group B vs HLA mismatches from group A (P = 0.002), group C vs group B (P < 0.005), patients who were not treated with total body irradiation at first autograft (P < 0.02) and patients in first remission at first autograft (P = 0.02). To conclude, the poor outcome in these patients was improved if a second autograft was feasible (P < 0.005), or if an HLA-matched allograft was performed (NS). Bone Marrow Transplantation (2000).     

不同治疗方案对70岁以上晚期肺腺癌患者生存期的影响

目的探讨不同治疗方案对70岁以上晚期肺腺癌患者预后的影响。方法回顾分析67例70岁以上晚期肺腺癌患者的治疗经过,根据所接受的治疗分为3组:靶向治疗组(A组)、化疗组(B组)和最佳支持治疗组(C组)。进一步将B组分为3个亚组:单纯化疗并完成首次4~6个治疗周期(B1组),在治疗中使用过靶向药物(B两组)和未完成4-6个化疗周期的患者(B3组),比较各组患者1年生存率,2年生存率,无进展生存期及生存期的差异。结果 A、B两组的1年生存率(35.3%,40.0%)均高于C组(6.6%)(P0.01),三组患者的2年生存率无显著差异。A、B两组的无进展生存期(6.9月,4.7月)均高于C组(2.2月)(P0.05)。A、B两组的中位生存期无显著差异(8.2月,9.1月),均高于C组(3.4月)(P0.01)。在亚组分析中,B1组和B两组的1年生存率高于B3组(分别为46.7%、58.3%及0.0%)(P0.05),3组患者的2年生存率分别为26.7%,41.7%和0.0%。B1组(5.1月)与B两组(4.5月)的无进展生存期均高于B3组(2.4月)(P0.01)。3组患者的中位生存期分别为11.7月,15.1月和3.2月,B1、B两组高于B3组(P0.01)。B1组的中位生存期比A组增加了3.7月(P0.05)。结论对于老年晚期肺癌患者,化疗或靶向治疗疗效均优于最佳支持组。化疗联合或交替使用靶向药物可能使该患者群体受益。     

Prevalence of enterobiasis and its incidence after blanket chemotherapy in a male orphanage

A prospective observational study was conducted in a male orphanage to find out the prevalence of enterobiasis and its incidence after blanket chemotherapy using mebendazole. We found that the prevalence of enterobiasis was 28.9%. The incidence density of enterobiasis after blanket chemotherapy was 379.82 per 1,000 person-years which was quite high. We suggest that blanket chemotherapy should be repeated at every 6 months interval to control enterobiasis in orphanages.     

Combination of ribavirin and interferon-alfa surpasses high doses of interferon-alfa alone in patients with genotype-1b-related chronic hepatitis C

The purpose of this study was to compare interferon-alfa alone (12-month course with high initial doses) with a combination of interferon-alfa and ribavirin in patients infected with genotype 1b. Three hundred and seven patients were randomized into 3 groups to receive 6 mega units (MU) of interferon-alfa-2b subcutaneously 3 times weekly for 6 months followed by 3 MU for 6 months (n = 95, group A); 10 MU for 3 months followed by 6 MU for 3 months, followed by 3 MU for 6 months (n = 83, group B); or the group-A schedule in combination with ribavirin (n = 129, group C) for 4 (n = 46), 6 (n = 44), or 12 months (n = 39). Negative polymerase chain reaction (PCR) was more frequent in group C than in groups A or B after 3 months of treatment (P <.006), at the end of treatment (P =.017), and at the end of follow-up (32.8%, 16.9%, and 14.1%, respectively, P <.003). A complete response (negative PCR and normal alanine transaminase) was higher in group C than in the other groups and when comparing 12- to 4- and 6-month combination therapy at the end of treatment (P =.05) and of follow-up (45.2% vs. 25.4%, respectively, P =.05). The greater efficacy of the combination was related to the higher rate of primary virological response and also to a decrease in the percentage of breakthrough and of relapse. In 1b-infected patients, the combination of high doses of interferon-alfa (6 MU) and ribavirin for 12 months appears to be the best therapy, with a high rate of sustained response.     

荷叶胶囊对人体血脂异常的调脂作用研究

目的:探讨荷叶水提物对人体血脂异常的调脂作用。方法:从郴州市各类人员体检检出的高脂血症者中,选择符合高血脂诊断标准的自愿者,共90人。随机分成3组,每组30人,即荷叶胶囊组(A组),洛伐他汀组(B组)和对照组(C组)。A组服用荷叶水提物制作的胶囊,4粒/次,3次/d;B组服用洛伐他订,20mg/次,1次/d,C组给予安慰剂;各组均进行健康教育和膳食指导,调脂40天。采用日本产全自动生化分析仪(OLYMPUS-640)测定调脂前、后的血清总胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白胆固醇(HDL-C)和低密度脂蛋白胆固醇(LDL-C)水平。结果:A组调脂后血清TC、TG、LDL-C水平明显下降,HDI-C水平明显升高,与调脂前比较有显著差异(P<0.001.<0.001,<0.002,<0.01);B组调脂后TC、TG、LDL-C水平亦明显下降(P<0.001,<0.05,<0,001),与A组无显著差异(P>0.05),但升高HDL-C效果不明显(P>0.05);C组调脂前、后血清TC、TG、LDL-C和HDL-C水平无显著差异(P>0.05),且调脂后的血脂水平明显高于A、B组(P<0.01)。结论;荷叶水提物对人体具较好的调脂作用,且无毒,未发现副作用。     

Improvement of prognosis for unresectable biliary tract cancer

AIM:To evaluate the chemotherapeutic outcomes and confirm the recent improvement of prognosis for unresectable biliary tract cancer.METHODS:A total of 186 consecutive patients with unresectable biliary tract cancer,who had been treated with chemotherapy between 2000 and 2009 at five institutions in Japan,were retrospectively analyzed.These patients were divided into three groups based on the year beginning chemotherapy:Group A(2000-2003),Group B(2004-2006),and Group C(2007-2009).The data were fixed at the end of December 2011.Overall survival and time-to-progression were analyzed and compared chronologically.RESULTS:No patient characteristics were significantly different among the three groups.The gallbladder was involved in about half of the patients in each group,and metastatic biliary tract cancer was present in three quarters of the enrollees.In Group A,5-fluorouracilbased chemotherapies were primarily selected as firstline chemotherapy,and only 24% were treated with second-line chemotherapy.In Group B,gemcitabine or S-1 monotherapy was mainly introduced as firstline chemotherapy,and 51% of the patients who were refractory to first-line chemotherapy were treated with second-line chemotherapy mainly with monotherapy.In Group C,the combination therapy with gemcitabine and S-1 was mainly chosen as first-line chemotherapy,and 53% of the patients refractory to first-line chemotherapy were treated with second-line chemotherapy mainly with combination therapy.The median timeto-progressions were 4.4 mo,3.5 mo and 5.9 mo in Groups A,B and C,respectively(4.4 mo vs 3.5 mo vs 5.9 mo,P < 0.01).The median overall survivals were 7.1,7.3,and 11.7 mo in Groups A,B and C(7.1 mo vs 7.3 mo vs 11.7 mo,P = 0.03).Induction rates of all three drugs(gemcitabine,platinum analogs,and fluoropyrimidine) in Groups A,B and C were 4%,2% and 27%(4% vs 2% vs 27%,P < 0.01).CONCLUSION:The prognosis of unresectable biliary tract cancer has improved recently.Using three effective drugs(gemcitabine,platinum analogs,and fluoropyrimidine) may     

Should aged patients with chronic hepatitis C be treated with interferon and ribavirin combination therapy?

The aim of this study was to investigate the efficacy and safety of combination therapy of interferon and ribavirin for aged patients with chronic hepatitis C. METHODS: This study was conducted at Osaka University Hospital and institutions participating in the Osaka Liver Disease Study Group on 329 patients with chronic hepatitis C receiving interferon and ribavirin combination therapy (group A, under 60 year old, n=199; group B, 60-64 year old, n=64; group C, over 65 year old (mean age, 67.8+/-2.2 year old, n=66)). Of the 293 patients who were tested for HCV serotype and HCV viral loads, 215 had HCV-RNA with serotype 1 and high viral loads (1H) and the other 78 had HCV-RNA with serotype 2 or low viral loads (non-1H). RESULTS: In per-protocol analysis, the overall SVR rate of 1H patients was 28% (51/184). Among the 1H patients, the SVR rate was significantly lower in group C (16%) and group B (17%) than in group A (34%) (p<0.05). The overall SVR rate of non-1H patients was 85% (57/67). No significant difference was found in the SVR rate among group C (79%), group B (100%), and group A (84%). On the other hand, the discontinuance of both drugs due to side effects was 29% (19/66) in group C, 20% (13/64) in group B, and 11% (21/199) in group A, with the discontinuance rates being higher in the older group (p=0.002). CONCLUSIONS: In aged chronic hepatitis C patients, interferon and ribavirin combination therapy can be recommended for the non-1H patients who showed a high SVR rate of approximately 65%, but not for the 1H patients.